{"id":"W4413318599","doi":"10.1007/s10637-025-01573-0","title":"Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor–relapsed tumors","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Colorectal cancer; Triple-negative breast cancer; Internal medicine; Oncology; Breast cancer; Metastatic breast cancer; Open label; Cancer; Cancer research; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001886351,0.0003346349,0.0008370262,0.0002098691,0.0001611988,0.00006392427,0.0001190092,0.00003982582,0.000191874],"category_scores_gemma":[0.00009292954,0.0002511643,0.00002820684,0.000811852,0.0002667015,0.0003654016,0.0001297642,0.0001574135,7.716186e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007117807,"about_ca_system_score_gemma":0.003017044,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02166635,"about_ca_topic_score_gemma":0.0293705,"domain_scores_codex":[0.9978592,0.0001087069,0.0007338264,0.0005342115,0.0003835125,0.0003805719],"domain_scores_gemma":[0.9989133,0.0001751077,0.000315891,0.0001305824,0.0002528371,0.0002122103],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4336935,0.03288449,0.2286561,0.00154792,0.006564808,0.0003947441,0.09631226,0.00155459,0.1054579,0.0005962175,0.00353469,0.08880274],"study_design_scores_gemma":[0.5773662,0.015076,0.2607554,0.002732331,0.001785791,0.00004671757,0.01947776,0.002054936,0.1187908,0.0008572938,0.0002423789,0.0008143171],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934637,0.0004608587,0.000003948171,0.001531749,0.0002071719,0.003478736,0.0007353442,0.00002135107,0.00009716587],"genre_scores_gemma":[0.9957746,0.0001820969,0.00143608,0.0001937181,0.00004459628,0.001348316,0.0001696005,0.00002488086,0.0008261531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1436727,"threshold_uncertainty_score":0.999994,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05132265043575454,"score_gpt":0.3734473502891841,"score_spread":0.3221246998534295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}